Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) FCF Margin (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed FCF Margin for 3 consecutive years, with 128046.88% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 12775339.0% to 128046.88% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 657.82% through Dec 2025, down 30833.0% year-over-year, with the annual reading at 657.82% for FY2025, 30833.0% down from the prior year.
  • FCF Margin hit 128046.88% in Q4 2025 for NewAmsterdam Pharma, down from 9428.45% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 43.2% in Q3 2024 to a low of 128046.88% in Q4 2025.
  • Historically, FCF Margin has averaged 12777.5% across 3 years, with a median of 1652.32% in 2023.
  • Biggest five-year swings in FCF Margin: soared 382569bps in 2024 and later plummeted -12775339bps in 2025.
  • Year by year, FCF Margin stood at 4119.18% in 2023, then surged by 93bps to 293.49% in 2024, then plummeted by -43530bps to 128046.88% in 2025.
  • Business Quant data shows FCF Margin for NAMS at 128046.88% in Q4 2025, 9428.45% in Q3 2025, and 197.23% in Q2 2025.